SILVER SPRING, Md. and SOUTH SAN FRANCISCO, Calif., June 23 /PRNewswire/-- The Pulmonary Hypertension Association (PHA) and Actelion PharmaceuticalsUS, Inc. today announced Robyn Barst as the recipient of the second annual PHAAward of Excellence in Pulmonary Arterial Hypertension (PAH) Care. The grant,in the amount of $50,000, will be awarded to an institution of Dr. Barst'schoice in order to support continued excellence in care for patients with PAH.The award, supported by Actelion, was presented at PHA's 8th International PHConference being held in Houston, Texas, this weekend.
Dr. Barst was selected for her outstanding contributions to PAH patientcare and clinical research, concentrated mainly on disease progression andtreatment of PAH. Her studies have focused on the genetic aspects of PAH andthe use of novel therapies for treatment.
"Dr. Barst has a well-established reputation of excellence in PAH clinicalresearch and medical care," said Michael McGoon, MD, Professor of Medicine andConsultant in Cardiology at the Mayo Clinic College of Medicine and chair ofthe Independent Award Selection Committee. "Her passionate desire to betterthe lives of PAH patients through careful and concentrated research epitomizesthe spirit of the PHA, and we are pleased to present this award in recognitionof her devotion."
The PHA Award of Excellence in PAH Care is designed to honor andacknowledge healthcare professionals who are committed to improving outcomesfor patients with PAH. It is awarded annually to outstanding care providersfor clinical practice excellence in the area of PAH. The financial componentof the award is directed to the recipient's choice of institution to supportcontinued excellence in care for patients with PAH.
"The PHA Award of Excellence will encourage advances in both patient careand research in the area of PAH, a serious condition that continues to beunder-recognized and under-treated," said Rino Aldrighetti, president of PHA."Our physicians have made significant progress over the past few years inimproving the lives of patients and developing effective PAH therapies, andbelieve that this award will contribute to ongoing advancement in PAH patientcare."
This year's award recipient was selected by the 2008-2009 IndependentSelection Committee, comprised of: Michael McGoon, MD, professor of medicineand consultant in Cardiology at the Mayo Clinic College of Medicine, chair ofthe Independent Selection Committee, and chair of PHA's Board of Trustees;David Badesch, MD, professor of medicine in the Divisions of PulmonarySciences and Critical Care Medicine, and Cardiology at the University ofColorado and chair of PHA's Scientific Leadership Council; Candi Bleifer, a PHpatient and PHA Board member; Linda Carr, parent of a PH patient and past PHAboard chair; Gregory Elliott, MD, professor of medicine at the University ofUtah School of Medicine and past chair of PHA's Scientific Leadership Council;and Jack Stibbs, parent of a PH patient and past PHA board chair. Criteria inselecting the recipients included: proven resources required for excellence inPAH patient care, service to the local community, and consistent provision ofcutting-edge options for patients living with PAH.
About the Award Recipient
Dr. Barst was most recently a Professor of Pediatrics in the Divisions ofPediatric Cardiology at Columbia University College of Physicians & Surgeonsand Cornell Medical Center in New York, and Director of New York PresbyterianPulmonary Hypertension Center at Columbia University Medical Center. Shereceived her medical degree from the University of North Carolina, ChapelHill, and completed an internship and residency in pediatrics as well asfellowships in pediatric cardiology and pediatric pulmonary medicine atColumbia University College of Physicians & Surgeons in New York.
Dr. Barst is a Fellow of the